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Abstract 
This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a 
reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the 
European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for 
Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a 
consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need fur-
ther updates as care evolves. The key recommendations are that bone pain or a palpable mass should always lead to 
further investigation and that patients with clinico-radiological findings suggestive of a primary bone tumour at any 
site in the skeleton should be referred to a specialist centre and managed by a fully accredited bone sarcoma multi-
disciplinary team. Treatment recommendations are provided for the major tumour types and for localised, metastatic 
and recurrent disease. Follow up schedules are suggested.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
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Background
Rationale and objective of guidelines
Bone sarcomas are uncommon malignancies and it was 
recognised more than 30  years ago that their manage-
ment should be centralized. Following various NHS 
reforms, the diagnosis and surgical treatment of primary 
bone sarcomas is now commissioned by the NHS Eng-
land Highly Specialized Commissioning Group [1] in 
five centres in England. However, other treatments such 
as chemotherapy and radiotherapy may be delegated to 
other centres. Arrangements in Scotland and Northern 
Ireland differ. The surgical treatment of patients in Wales 
takes place in specialist centres in England, with other 
modalities of treatment delivered within Wales.
This reference document aims to improve the quality 
of care for patients with bone tumours by identifying and 
informing key management decisions and is an update of 
the 2010 British Sarcoma Group (BSG) guidelines [2].
Methods
In developing these guidelines, the following were con-
sulted: The National Comprehensive Cancer Network 
(NCCN) Clinical Practice Guidelines [3]; ESMO/Euro-
pean Network Working Group, Clinical Practice Guide-
lines for Bone Sarcomas [4]; National Institute for Health 
and Care Excellence (NICE) Quality Standard [QS78] 
Sarcoma [5] and Suspected cancer: recognition and refer-
ral guideline [NG12] [6] and the published literature from 
2010 to 2015. The authors considered the applicability to 
UK practice and reached consensus on the content. The 
document was then circulated widely within the British 
Sarcoma Group for comment and approval.
Scope of guidelines
The guidelines apply to all primary bone sarcomas (and 
giant cell tumours of bone) arising in any skeletal loca-
tion. These guidelines consider clinical effectiveness, 
and include treatments to which a specialist bone sar-
coma multidisciplinary team (MDT) in the UK should 
have access. While representing a broad consensus in 
2015, these guidelines will require updating as treatment 
evolves. Haemopoietic tumours of bone, rehabilitation, 
prosthetic services and palliative care are not included.
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Classification of bone sarcomas
Primary malignant bone tumours comprise 0.2  % of all 
cancers diagnosed in England and have an annual inci-
dence of around 7.9 per million [7]. On average, 380 peo-
ple were diagnosed with primary bone sarcomas each year 
in England between 1985 and 2009. Therefore, a General 
Practitioner (GP) is unlikely to see a patient with a bone 
sarcoma in a working lifetime. Delays in diagnosis are 
common. Reducing delays would almost certainly lead to 
improved survival outcomes and less extensive surgery [8].
Despite their rarity, primary malignant bone tumours 
comprise approximately 5  % of all childhood cancers in 
European Countries [7, 9] and include two major cancers 
of children and young adults: osteosarcoma and Ewing 
sarcoma [7]. In children under 5 years of age, a destruc-
tive bone lesion is more likely to be metastatic neuroblas-
toma or eosinophilic granuloma [4, 10]. Chondrosarcoma 
is more common in middle aged and elderly people [7].
In adults, especially those over 40  years of age, meta-
static carcinomas (usually from lung, breast, thyroid, 
kidney or prostate) and haemopoietic malignancies (e.g. 
plasma cell tumour or lymphoma) in bone considerably 
outnumber primary bone tumours. At any age the pos-
sibility of a benign lesion or infection must be consid-
ered [11]. If there is diagnostic uncertainty, it should be 
assumed the patient has a primary bone sarcoma until 
proven otherwise [12].
There has been no significant improvement in 5-year 
overall survival rates for patients with bone sarcomas 
over the past 25–30 years, with rates static at between 53 
and 55 % [7, 13].
A classification of bone sarcomas adapted from the 
World Health Organization (WHO) classification of pri-
mary bone tumours is shown in Table 1 [14].
Although some inherited and acquired factors are asso-
ciated with the development of primary bone tumours, a 
cause cannot be identified in the majority of patients [15, 
16].
The 5-year relative survival for patients diagnosed in 
England in 1985–2004 is considerably lower than that 
reported within the US Surveillance, Epidemiology and 
End Results (SEER) programme (66  %) [17]. This may 
reflect the fact that patients in the SEER programme are 
younger (30  % of NCIN patients were >65  years, com-
pared with 21 % of SEER patients: 22 % of NCIN patients 
were <19  years, compared with 29  % of SEER patients). 
Furthermore, the SEER programme does not specify 
which morphological sub-types are included. Further 
investigation is required [7].
Osteosarcoma
Osteosarcoma is the second most frequent primary can-
cer of bone and accounts for over 10 % of all solid cancers 
in adolescents (age 15–19). Another peak in incidence 
occurs in the seventh and eighth decades of life [7, 13]. 
It is slightly more common in males (male to female 
ratio 1.4:1.0) [7]. Survival rates are significantly higher 
in younger patients (5-year survival, <40  years 53  % vs. 
>40 years 22 %; p < 0.0001) [7, 13].
Osteosarcoma usually arises in the metaphysis of an 
extremity long bone, most commonly around the knee 
[18, 19]. Some tumours (predominantly in adults) arise in 
the axial skeleton, pelvis or craniofacial bones. Risk fac-
tors for osteosarcoma include previous radiation therapy, 
Paget’s disease of bone and germline abnormalities such 
as Li-Fraumeni syndrome, Werner syndrome, Rothmund 
-Thomson syndrome and familial retinoblastoma [20, 
21]. The temporal association of osteosarcoma with the 
pubertal growth spurt and the location in the metaphy-
sis of long bones suggest an association with rapid bone 
growth.
Ewing sarcoma
Ewing sarcoma is the second most common primary 
malignant bone tumour in children and adolescents, 
but is also seen in adults. The median age at diagnosis is 
around 15 years and in the UK there is a male preponder-
ance of 1.5:1 [7]. It is less common in people of Chinese 
or Black African origin. Identification of chromosomal 
translocations specific to Ewing sarcoma e.g. (t11;22) 
have provided a useful diagnostic criterion. In recent 
years undifferentiated bone sarcomas with morphological 
Table 1 Classification of malignant primary bone tumours 
(adapted from WHO classification [14])
Chondrogenic tumours (1) Atypical cartilaginous tumour/ 
chondrosarcoma (grade I)
(2) Chondrosarcoma (grades II/III)
(3) Dedifferentiated chondrosarcoma
(4) Mesenchymal chondrosarcoma
(5) Clear cell chondrosarcoma
Osteogenic tumours (1) Low-grade central osteosarcoma
(2) Conventional (high-grade) osteosarcoma 
(chondroblastic fibroblastic osteoblastic)
(3) Telangiectatic osteosarcoma




(8) High-grade surface osteosarcoma
Notochordal tumours Chordoma
Vascular tumours (1) Epithelioid haemangioendothelioma
(2) Angiosarcoma
Other malignant  
mesenchymal tumours
Fibrosarcoma, Leiomyosarcoma,  
Liposarcoma etc.
Miscellaneous tumours (1) Ewing sarcoma
(2) Adamantinoma
(3) Undifferentiated high-grade pleomorphic 
sarcoma of bone
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features of Ewing sarcoma but with uncharacteris-
tic translocations e.g. CIC-DUX have been described. 
Although clinical information is limited these appear to 
respond less well than Ewing sarcoma to chemotherapy 
and may have an unfavourable prognosis [22].
The most frequent anatomical sites of involvement of 
Ewing sarcoma are the long bones, pelvis, ribs and verte-
bral column. All forms of Ewing Sarcoma are high grade 
[23, 24].
Chondrosarcoma
Chondrosarcoma most commonly presents between 30 
and 60 years of age [7]. The ageing UK population means 
that chondrosarcoma has become the most common 
bone sarcoma, ahead of osteosarcoma [25]. Differentiat-
ing between an atypical enchondroma and a low grade 
chondrosarcoma can be extremely difficult and has led 
to these tumours being categorised together in the WHO 
classification as atypical cartilaginous tumour/chondro-
sarcoma grade I. It is considered to be a tumour of inter-
mediate malignancy, most often behaving in a locally 
aggressive fashion and rarely metastasising. Care must 
be taken not to overtreat benign tumours or undertreat 
malignant ones [26].
Most chondrosarcomas are located in long bones but 
they also arise in flat bones (e.g. pelvis, rib and scapula). 
Chondrosarcomas arising in pre-existing benign lesions 
such as osteochondromas and enchondromas are known 
as secondary peripheral chondrosarcomas and secondary 
central chondrosarcomas respectively. The risk of devel-
oping chondosarcoma in solitary osteochondromas and 
enchondromas is uncertain, but is increased when there 
are multiple lesions or when lesions are located in the 
axial skeleton, particularly the pelvis [27].
The majority of primary chondrosarcomas are low- 
rather than high-grade [28] and are of the conventional 
subtype. Rare subtypes include mesenchymal chondro-
sarcoma and clear cell chondrosarcoma. In rare circum-
stances, conventional chondrosarcomas “dedifferentiate” 
into very high-grade tumours (so-called de-differentiated 
chondrosarcoma) [29–31] with a poor prognosis.
Undifferentiated pleomorphic sarcoma of bone
Undifferentiated pleomorphic sarcoma (UPS) of bone is 
a relatively recent term for sarcomas that do not exhibit 
a specific line or pattern of differentiation (previously 
termed malignant fibrous histiocytoma of bone) [32, 33]. 
UPS of bone is typically high-grade with metastatic rates 
of at least 50 % [33]. Treatment usually involves neoadju-
vant therapy followed by wide excision. Its chemosensi-
tivity and survival rate are similar to osteosarcoma [34]. 
Occasionally, an undifferentiated pleomorphic sarcoma is 
found to be a dedifferentiated chondrosarcoma or osteo-
sarcoma after resection.
Chordoma
Chordomas develop from persistent notochordal ele-
ments, and originate from the sacrum (50 %), skull base 
(30  %), and mobile spine (20  %). Extraskeletal tumours 
are very rare. Chordoma is a locally invasive, typically 
low-grade tumour but infrequently (around 5  %) highly 
malignant dedifferentiated cases occur [35]. Metasta-
ses develop in 30–40  % of patients, typically late in the 
disease trajectory and usually after local recurrence. 
Metastases can occur in lung, liver, bone, subcutis, lymph 
nodes and other sites.
Adamantinoma
Adamantinoma is a rare, low-grade malignant neoplasm 
that arises in the tibia, fibula or both bones, although 
it has rarely been reported in other bones [36]. Ada-
mantinoma accounts for 0.3–1  % of all malignant bone 
tumours and occurs mostly in young to middle-aged 
adults (20–40 years of age), with a male-to female ratio of 
1.3:1. The tibial shaft (medial or distal) is most commonly 
affected. The tumour has lytic and sometimes destructive 
areas which can lead to fracture [37]. Recurrence is late 
(can be >20 years) but frequent (about 30 %) after incom-
plete excision. The rate of metastasis is 10 % to 20 %, usu-
ally to lung [36].
Giant cell tumour of bone
Giant cell tumours of bone are generally considered 
benign but locally aggressive tumours; there is a low risk 
of metastasis, particularly after local recurrence [38]. 
Giant cell tumours rarely appear before skeletal maturity 
and most often affect patients between 20 and 30  years 
of age [39]. Tumours characteristically occur at the end 
of a long bone in a juxtaarticular location. Histologically 
tumours contain a proliferation of mononuclear stromal 
cells amongst which are scattered numerous multinucle-
ated giant cells that have been identified as osteoclasts 
recruited by the RANK-ligand expressing stromal cells. 
Tumours cause local destruction of bone and may be 
associated with a soft tissue mass or pathological fracture 
[40].
Other malignant mesenchymal tumours
Very rarely malignant mesenchymal tumours that more 
commonly arise in soft tissues can present as a primary 
(often spindle cell) sarcoma of bone. These include 
spindle cell malignancies such as leiomyosarcoma and 
fibrosarcoma. In general, spindle cell sarcomas are 
thought to represent between 2 and 5 % of primary bone 
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malignancies. Spindle cell sarcomas arise in a similar age 
group to chondrosarcoma but the skeletal distribution 
is similar to osteosarcoma. There is a high incidence of 
fracture at presentation. Associations with pre-existing 
conditions (e.g. Paget’s disease or bone infarct) or previ-
ous irradiation have been reported [41].
Presentation and referral
The most common symptom of a primary malignant 
bone tumour is pain, which may gradually increase in 
intensity [42]. Bone pain at night should always be con-
sidered a ‘red flag’ symptom requiring further investi-
gation. Pain levels may vary and a bone swelling or soft 
tissue mass may develop later. Even high-grade tumours 
do not usually cause systemic symptoms; when present 
these may indicate metastatic disease [42]. The average 
duration of symptoms is 3 months, although 6 months or 
longer is not uncommon [8, 43, 44].
A plain x-ray is the first investigation of choice. The 
presence of any of the following X-ray features is sugges-
tive, but not diagnostic, of a primary bone tumour and 
should be investigated further, usually following urgent 
referral to a bone sarcoma MDT:
  • Bone destruction
  • New bone formation
  • Periosteal swelling
  • Soft tissue swelling
Additionally, it must be remembered that a ‘normal’ 
x-ray does not rule out bone sarcoma; persistent bone 
pain/night pain should still require urgent MRI scan/
referral to a sarcoma centre. Hip and knee pain in chil-
dren is often attributed to sporting injury with early ‘nor-
mal’ looking x-rays.
In all patients a full clinical history should be taken 
(including duration, intensity and diurnal variation of 
pain, prior benign or malignant tumours, family history 
and previous radiotherapy) and examination performed 
(with specific attention to the size, consistency, mobility, 
and location in relation to bone of any mass and palpa-
tion of regional and local lymph nodes), considering the 
most likely diagnosis for a patient of a given age. Recent 
injury does not rule out a primary bone tumour and 
should not prevent further examination.
In patients under 40  years of age, investigations prior 
to referral should include X-ray of the affected bone (in 
two planes) and simple blood tests [full blood count 
(FBC), erythrocyte sedimentation rate (ESR), biochemi-
cal profile including alkaline phosphatase (ALP)]. Further 
urgent imaging of the local site with magnetic resonance 
imaging (MRI) or computed tomography (CT) is usually 
required, prior to or after referral [8].
In patients over 40 years of age more extensive inves-
tigation before referral is appropriate (if it can be done 
quickly) as the most likely diagnosis is of metastatic car-
cinoma in bone. Appropriate investigations include CT 
of chest, abdomen and pelvis, isotope bone scan, and 
myeloma screen. If the bone lesion is solitary the patient 
should be referred to a reference centre to exclude a pri-
mary malignant bone tumour.
All patients with a possible diagnosis of a primary bone 
tumour should be referred urgently under the 2  week 
wait pathway to a fully accredited bone sarcoma MDT 
[4, 45, 46]. This core principle is embedded in the NICE 
‘Improving Outcomes for People with Sarcomas’ guid-
ance [47], ‘Children and Young People with Cancer’ guid-
ance [48] and the NICE Quality Standard QS78 Sarcoma 
[5].
Referral before biopsy is essential to ensure optimal 
diagnosis and management [49, 50] since poorly planned 
or executed biopsies can compromise future treatment 
[42].
Networks should ensure GPs are aware of and comply 
with the urgent referral criteria in the NICE Suspected 
cancer: recognition and referral guideline NG12 [6] and 
that GPs and hospital doctors are aware of the local diag-
nostic pathways for patients with suspected primary 
bone tumours. There are also referral guidelines specific 
to Scotland which can be found at healthcare improve-
ments Scotland [51].
UK reference centres
Royal National Orthopaedic Hospital Stanmore, London
 Phone 020 8909 5112




Royal Orthopaedic Hospital Northfield, Birmingham
 Phone 0121 685 4150
 Fax 0121 685 4146
Nuffield Orthopaedic Centre Oxford
 Phone 01865 738061
 Fax 01865738037




 Phone 0191 233 6161 or 0191 213 7708
 Fax 0191 233 1328
 www.newcastlesarcoma.org.uk
Greater Manchester and Oswestry Sarcoma Service,
 Robert Jones and Agnes Hunt Hospital
 Oswestry
 Phone 0845 838 3429
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 Fax 0845 838 3428
Scotland: The Scottish Sarcoma Network,
 Glasgow Royal Infirmary
 Glasgow G4 0SF
 Phone 0141 232 1034 or 07951 273920
 www.ssn.scot.nhs.uk
In Scotland sarcomas are managed under the umbrella 
of the Scottish Sarcoma Network, which includes cen-
tres in Edinburgh, Glasgow and Aberdeen with a shared 
MDT. Links to the three national networks can be found 
at the West of Scotland Cancer Network (WoSCAN) 
[52].









  • The most common symptom of a primary bone 
tumour is pain which may gradually increase or vary 
in intensity. Bone pain at night should always be con-
sidered a ‘red flag’ symptom requiring further inves-
tigation.
  • The presence of pain or a palpable mass arising from 
any bone requires further investigation. A plain X-ray 
is the first investigation of choice.
  • The presence of radiological features including bone 
destruction, new bone formation, periosteal swell-
ing and/or soft tissue swelling are suggestive, but 
not diagnostic, of a bone tumour and require further 
investigation.
  • Networks should ensure that GPs are aware of and 
comply with the urgent referral criteria in the NICE 
‘Suspected cancer: recognition and referral guidlines’ 
and ‘Cancer referral guidelines for Scotland’ and that 
GPs and hospital doctors are aware of the diagnostic 
pathways for patients with suspected primary bone 
tumours.
  • All patients with a provisional histological and/or 
radiological diagnosis of bone sarcoma should have 
their diagnosis reviewed by a specialist sarcoma 
pathologist and/or radiologist, both of whom should 
be part of a bone sarcoma MDT.
Investigation
Imaging
All patients should have X-rays in two planes at 
presentation.
Further local site imaging should be with MRI [42], 
including the whole anatomical compartment, the involved 
bone and adjacent joints [53]. CT is helpful if there is diag-
nostic uncertainty or MRI is contraindicated, and may bet-
ter visualise areas of microcalcification, periosteal bone 
formation and cortical destruction. CT is routinely used 
in addition to MRI for pelvic tumours. Dynamic contrast 
enhanced MRI may identify high-grade areas within a 
chondrosarcoma, and therefore guide biopsy.
Staging investigations for patients with confirmed pri-
mary malignant bone tumours should include chest radi-
ography and/or CT. CT is the technique of choice for 
imaging the chest, pelvis and mandible [53–55]. If inde-
terminate nodules are detected in the lungs, an interval 
scan may be indicated. All suspicious chest CTs should 
be reported by a radiologist experienced in bone sarcoma 
or sent to an MDT for review.
Whole body bone scintigraphy will detect lesions else-
where in the skeleton [24]. Whole body MRI and posi-
tron emission tomography (PET) may be considered for 
staging and treatment response evaluation [54, 56–58]. 
A recent retrospective study of 91 patients with Ewing 
sarcoma [57], concluded that F-18-deoxy-d-glucose posi-
tron emission tomography (18FDG-PET) may be suffi-
cient for initial screening of osseous metastases and also 
identified all patients with bone marrow metastases.
During chemotherapy clinical assessment (pain and 
clinical measurement) and imaging of the local site and 
lungs by MRI, chest X-ray and CT may be helpful to eval-
uate response to chemotherapy [53, 59].
Staging systems
Two staging systems are in widespread use, the Enneking 
[60] and the TNM system (American Joint Committee 
on Cancer–AJCC/International Union against cancer–
UICC) [61].
The Enneking system is based on histological grade 
(I =  low and II =  high grade) and extent in relation to 
the anatomical compartments of the limb (a = intracom-
partmental, b = extracompartmental). If the bone cortex 
is intact and there is no soft tissue mass, the tumour is 
considered intracompartmental. Stage III tumours have 
metastases, but can be high or low grade. The TNM 
(AJCC/UICC) system is based on tumour grade, size and 
the presence of metastases (Table 2).
Laboratory tests
There are no specific laboratory tests for the diagnosis of 
bone sarcoma. However, the following are of prognos-
tic value: erythrocyte sedimentation rate (ESR), alkaline 
phosphatase (ALP) and lactate dehydrogenase (LDH) [62, 
63].
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Other baseline assessments
Around 10  % of Ewing sarcomas metastasise to bone 
marrow, and therefore bone marrow biopsy should be 
routinely performed as a staging investigation [42].
Chemotherapy treatment can result in renal, cardiac 
and auditory dysfunction [64]. Pretreatment evaluation 
should therefore include baseline renal function test-
ing (e.g. urea, creatinine, glomerular filtration rate) and 
assessment of cardiac function (e.g. echocardiogram, 
MUGA [multi-gated acquisition scan]). An audiogram is 
recommended for patients due to receive cisplatin.
Sperm storage is recommended for male patients of 
reproductive age. For female patients, a fertility physi-
cian may be consulted to discuss options for fertility 
preservation.
Biopsy
Biopsy is the definitive diagnostic test. Biopsy of a sus-
pected primary malignant bone tumour should be car-
ried out at a specialist sarcoma reference centre by, or 
in consultation with, the surgical team who will perform 
definitive tumour resection [47]. This improves access to 
modern molecular diagnostic techniques and ensures the 
biopsy track can be excised at the time of definitive sur-
gery. Inappropriate biopsy can compromise limb salvage 
or even cure. The principles of biopsy [49] are:
  • Biopsy should only be done after local imaging of the 
affected bone to allow planning of the approach and 
most representative area to biopsy.
  • There should be minimal contamination of normal 
tissues.
  • In many situations, core needle biopsy will be ade-
quate, often guided by ultrasound, X-ray or CT.
  • Samples should always be taken for microbiologi-
cal assessment as well as histology and cytogenetic/
molecular genetic studies.
  • Where possible, samples should be snap frozen for 
storage in a tumour bank for future research studies 
with patient consent.
  • Samples must be interpreted by an experienced bone 
tumour pathologist.
  • The pathology request form should ensure sufficient 
detail to make a diagnosis, including anatomical site, 
patient age and the radiological differential diagnosis.
CT-guided biopsies [65, 66] are most appropriate for 
deeper locations (e.g. pelvis) or to target a particular area 
of concern within the tumour (e.g. a possibly dedifferen-
tiated area in a chondrosarcoma). Frozen sections can 
help to confirm that lesional tissue has been obtained, 
but they should not be relied upon for a definitive diag-
nosis and may use up a significant volume of potentially 
diagnostic material. Biopsy tracks should be clearly 
marked with a small incision or tattoo to ensure they are 
excised at the definitive procedure.
Biopsy of other indeterminate lesions should always be 
considered if management might change as a result (e.g. 
entry into a trial or a decision to amputate).
Laminectomy or decompression for spinal tumours 
should be avoided at diagnosis unless necessary to relieve 
spinal cord compression, and after consultation with a 
member of the bone sarcoma MDT.
Pathology
Pathologists reporting biopsies and/or resections of bone 
sarcomas should be accredited bone tumour pathologists 
and members of a bone sarcoma MDT.
Reports should comply with Royal College of Patholo-
gists guidance [67].
The biopsy report should include a description of the 
specimen, the microscopic findings and the histological 
diagnosis.
The pathology report relating to the definitive resec-
tion specimen should include a gross description record-
ing the location and size (measured in three dimensions 
in mm) of the tumour. It should note the extent of local 
tumour spread and involvement of specific anatomical 
compartments. Resection margins should be reported 
as clear or involved by tumour. The distance (in mm) of 
infiltrating tumour from the nearest resection margin 
and the nature of tissue at this margin should be speci-
fied. The histological features of the tumour and results 
of relevant further investigations (e.g. immunohisto-
chemistry or molecular genetics) should be recorded. The 
tumour type (and subtype) should be recorded in keep-
ing with the latest WHO criteria [14]. The tumour type 
should be coded using the systematized nomenclature of 
medicine—clinical terms (SNOMED-CT) codes [68].
Molecular genetics and pathology
Tissue banks are essential for diagnostic and transla-
tional research in cancer; therefore, informed consent 
for tumour banking, analysis and research should be 
sought according to local practice wherever possible. In 
Table 2 AJCC/UICC Staging [61]
Stage Grade Size (cm) Metastases
1° Low grade ≤8 None
1b Low grade >8 None
2° High grade ≤8 None
2b High grade >8 None
3 Any grade Any Skip metastases
4 Any grade Any Distant metastases at diagnosis
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specialist centres, storage of fresh frozen tissue should be 
undertaken in every case where consent has been given.
Although most Ewing sarcomas can be recognised 
morphologically and by immunohistochemical identifica-
tion of the surface glycoprotein CD99, molecular genetic 
confirmation of a Ewing sarcoma translocation is recom-
mended, particularly if the clinicopathological presenta-
tion is unusual or the histological diagnosis is doubtful. A 
reference laboratory for Ewing sarcoma diagnosis should 
have both interphase fluorescence in  situ hybridisation 
(FISH) and reverse transcription—polymerase chain 
reaction (RT-PCR) technology available [69] and should 
participate in an external quality assurance programme.
Confirmation of diagnosis
To confirm the diagnosis and minimise the risk of diag-
nostic and management errors, all patients with sus-
pected bone tumours should be discussed by a bone 
sarcoma MDT with a surgeon, radiologist, pathologist 
and oncologist who have access to the relevant informa-
tion and biopsy material [47].
Key recommendations
  • Patients with suspected primary bone tumours 
should have access to timely and appropriate imag-
ing.
  • The definitive diagnostic test is a biopsy, which 
should be carried out at or in consultation with the 
team in a reference centre.
  • All patients should have tissue stored for subsequent 
investigation with appropriate consent, including fro-
zen tissue, when possible.
  • Both the diagnostic and resection specimens should 
be examined by an accredited bone tumour patholo-
gist who is part of a bone sarcoma MDT. The pathol-
ogy report should comply with the Royal College of 
Pathologists guidance.
  • In every case the diagnosis must be confirmed by ref-
erence to clinical findings, laboratory investigation 
and radiological imaging at a bone sarcoma MDT.
  • Patients with a confirmed diagnosis should be staged 
according to AJCC criteria.
  • Where treatment may have an impact on fertility, 
patients should be referred to the appropriate repro-
ductive medicine service before commencing treat-
ment.
Overview of management
As well as having care delivered or supervised by a spe-
cialist bone sarcoma MDT, patients should be allocated a 
key worker. Children, teenagers and young adults should 
also be discussed at the relevant children’s or TYA (young 
adult) MDT. This requires sufficient specialist staff to 
ensure age-appropriate care. A bone sarcoma MDT 
should be properly constituted, adhering to the require-
ments for core membership of the relevant specialties, 
and meeting minimum criteria for the number of patients 
treated each year; they should collect data on patients, 
tumours, treatment and outcomes as agreed nationally 
and participate in national audit.
Where possible and where trials are available, patients 
should be supported to participate in clinical trials. 
Lists of clinical trials in the National Institute for Health 
Research portfolio can be found on the UK Clinical 
Research Network Study Portfolio website [70] and the 
National Cancer Research Institute Clinical Trials web-
site [71].
Chemotherapy
Chemotherapy is part of standard treatment for osteo-
sarcoma, Ewing sarcoma, undifferentiated pleomorphic 
sarcoma and spindle cell sarcoma. Treatment of chon-
drosarcoma remains predominantly surgical, although 
chemotherapy may have a role in dedifferentiated and 
mesenchymal subtypes.
Management usually comprises preoperative neoadju-
vant systemic combination chemotherapy, local surgery 
and post-operative adjuvant chemotherapy [64]. While 
the main aim of neoadjuvant chemotherapy is to decrease 
the incidence of a subsequent distant relapse [72, 73], it 
may also help control the primary tumour.
Surgery
Decisions about the optimal surgical procedure for the 
primary tumour (i.e. limb salvage or amputation) require 
MDT discussion, considering tumour size and involve-
ment of anatomical structures, response to neoadjuvant 
therapies and patient preference. Surgical reconstruction 
may be influenced by patient and surgeon choice and 
should follow open discussion of the risks and benefits of 
available options and expected functional outcomes.
The aim of curative surgery is to resect the whole 
tumour with adequate margins. Where possible, wide 
en-bloc resection of the affected part of the bone and 
involved soft tissue should be performed. Close surgical 
margins may be marked with (MRI-inert) haemo-clips 
placed in the surgical field. In Ewing sarcoma, surgery 
should involve removal of all anatomical structures 
involved in the original prechemotherapy tumour volume 
where feasible. The specimen should be orientated to 
allow the pathologist to describe the anatomical location 
and thickness of surgical margins.
Surgical excision of local recurrence or metastatic dis-
ease requires discussion in a bone sarcoma MDT.
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Requirements for the surgical report
The surgeon should describe the procedure performed 
and the tissues resected. The planned surgical margin 
should be identified, along with areas of concern where 
the resection was close to tumour or gross tumour 
was encountered. The type of reconstruction should 
be described as well as postoperative care, including 
expected rehabilitation. The use of prophylactic antibi-
otics and thromboprophylaxis (e.g. mechanical and/or 
chemical agents) should be clearly stated.
Radiotherapy
Radiotherapy is frequently used in the definitive man-
agement of the primary tumour for Ewing sarcoma, but 
the relative radio-resistance of osteosarcoma and chon-
drosarcoma means it is only used as definitive treatment 
if there is no surgical option. Radiotherapy is not given 
routinely post-operatively, although it may be used in 
selected high-risk cases. However, radiotherapy has a pal-
liative role in all tumour types.
Although considered exploratory, heavy particle ther-
apy with protons or carbon ions, often in combination 
with photons, is increasingly used to treat unresectable 
primary bone sarcomas [74–76]. Excellent outcomes are 
reported for skull base chondrosarcomas or chordomas 
in which proton beam radiotherapy combined with sur-
gery can achieve local control rates of approximately 
70–90 % [77–79]. In unresectable or incompletely resect-
able osteosarcoma the five-year disease free survival 
(DFS) was 65  %, and the 5-year overall survival (OS) 
was 67  % [80]. High local control rates have also been 
achieved in sacral chordomas [81, 82].
At present there is no proton facility in the United 
Kingdom, but cases can be submitted to the UK Proton 
Panel to consider funding for treatment overseas. Refer-
ral guidelines can be found at the UK NHS England 
Commissioning website [83].
Prevention and management of pathological fracture
Patients with an existing or impending pathological frac-
ture associated with a suspected primary bone tumour 
should be managed with external splintage or immo-
bilisation and appropriate pain control until a diagno-
sis is established by local imaging (MRI and/or CT) and 
biopsy. Internal fixation is contraindicated.
Although pathological fracture is an adverse prognos-
tic factor for survival in osteosarcoma, and is likely to be 
associated with an increased risk of local recurrence [84], 
it does not preclude limb sparing surgery [85].
Fractures often heal during neoadjuvant chemother-
apy and allow subsequent resection of the tumour and 
involved soft tissues. Amputation may still be indicated 
if tumours fail to show a radiological response and/or 
resection of the tumour and the contaminated area can-
not safely leave a useful limb [86]. Adjuvant radiotherapy 
may decrease the risk of local recurrence in osteosar-
coma and may have a role in other tumour types after 
pathological fracture [87].
Thoracotomy
Pulmonary metastatectomy may be indicated in the pres-
ence of oligometastatic disease where the patient can be 
rendered disease free. Thoracotomy with manual explo-
ration of both lungs is strongly recommended, even when 
imaging studies suggest unilateral disease. Thoracoscopic 
techniques are strongly discouraged, as they lack sen-
sitivity and may be associated with an increased risk of 
intraoperative tumour dissemination [88].
Key recommendations
  • All patients with a confirmed diagnosis of bone sar-
coma should have their care supervised by a bone 
sarcoma MDT and be allocated a key worker. Chil-
dren, teenagers and young adults should also be 
discussed at the relevant children’s or TYA (young 
adult) MDT.
  • Networks should ensure that they meet the needs 
of children and young people with cancer with suf-
ficient specialist staff and care and facilities appropri-
ate to the child or young person’s age.
  • A bone sarcoma MDT should meet minimum cri-
teria for the number of patients treated in each year 
and adhere to the requirements for core membership 
of the relevant specialties.
  • All bone sarcoma MDTs should collect data on 
patients, tumours, treatment and outcomes as agreed 
nationally.
  • Patients should undergo definitive resection of their 
sarcoma by a surgeon who is a core or extended 
member of a bone sarcoma MDT or by a surgeon 
with tumour site specific or age appropriate skills in 
consultation with the bone sarcoma MDT.
  • When considering the local treatment of bone 
tumours, options for amputation or limb sparing sur-
gery should be tailored to the needs of the patient.
  • Chemotherapy and radiotherapy are important com-
ponents of the treatment of some patients and should 
be carried out at designated centres by appropriate 
specialists as recommended by a bone sarcoma MDT.
  • For pulmonary metastatectomy, open thoracotomy is 
recommended over endoscopic techniques.
Specific treatment
Osteosarcoma
Adverse prognostic factors for osteosarcoma include 
detectable metastases at presentation, axial or proximal 
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extremity tumour site, large tumour volume, elevated 
ALP or LDH, older age, high body mass index (BMI) at 
diagnosis, poor histological response to preoperative 
chemotherapy or pathological fracture [62, 89–91]. There 
is some evidence that females may have better outcomes 
than males [91] and patients >18 years may have poorer 
outcomes than younger patients [92].
Localised disease
Curative treatment for high-grade osteosarcoma con-
sists of surgery and chemotherapy [88, 93]. Compared 
with surgery alone, multimodal treatment of high-grade 
osteosarcoma increases survival from only 10–20  % to 
around 60  % [94, 95]. Whenever possible, patients with 
osteosarcoma should receive chemotherapy within a pro-
spective trial. Chemotherapy is also recommended for 
older patients with osteosarcoma using adapted proto-
cols [96].
Treatment commonly takes 6–9  months, comprising 
10 weeks of neoadjuvant therapy, surgical resection and 
adjuvant chemotherapy.
Although neoadjuvant treatment is not proven to add 
survival benefit over postoperative chemotherapy alone, 
advantages include: rapid improvement in symptoms; 
early treatment of micrometastatic disease; facilitation 
of resection in responsive tumours; it allows time to 
manufacture customised endoprosthesis and provides 
prognostic information about histological response [42, 
45, 97].
The most accepted regimen is induction therapy with 
MAP (high-dose methotrexate (HDMTX), doxorubicin 
and cisplatin). This is recommended in the UK for 
patients with potentially resectable tumours [98] and was 
chosen for the EURAMOS study1 (Table 3).
If not tolerated, the regimen may be modified to AP 
alone for patients >40  years old. Impaired renal func-
tion can cause delayed clearance of methotrexate result-
ing in mucositis and nephrotoxicity and therefore close 
monitoring is required. Combination regimens without 
methotrexate can be effective in patients intolerant of 
HDMTX or where pharmacokinetic monitoring is not 
available [99].
The goal of surgery is to safely remove the whole 
tumour whilst preserving as much function as possible. 
Most patients with extremity tumours are candidates 
for limb salvage if adequate surgical margins can be 
achieved. Where possible, wide surgical margins should 
be achieved to reduce the risk of recurrence [100]. It is 
accepted that a good (>90  %) histological necrosis rate 
1 EURAMOS is a collaboration of the Children’s Oncology Group (US) the 
Co-operative Osteosarcoma Study Group (European) the European Osteo-
sarcoma Intergroup and the Scandinavian Sarcoma Group. Collectively 
these groups represent the largest ever clinical experience in osteosarcoma.
after chemotherapy may allow a closer margin of excision 
to be considered safe. In patients with a poor response 
to chemotherapy and ‘close’ margins there is insufficient 
evidence to advise as to whether amputation offers a bet-
ter outcome even accepting the increased rate of local 
recurrence with limb salvage [86].
The benefit of adjuvant therapy compared with sur-
gery alone was demonstrated many years ago [104] and 
long-term (>25  years) follow-up has shown that a sta-
tistically significant survival benefit is maintained [105]. 
Adjuvant therapy may involve the same regimen as the 
induction phase or may be modified, but the ideal com-
bination regimen and the optimal treatment duration 
for certain clinical situations are yet to be defined [93, 
106].
Immune modulation has been proposed as a possible 
treatment in bone sarcomas. The immune modulator 
liposomal muramyl tripeptide (mifamurtide) added to 
postoperative chemotherapy demonstrated a statistically 
significant advantage in overall survival and a trend in 
event-free survival in a large randomised trial [101] and 
has been approved in Europe for patients under 30 with 
completely resected localised osteosarcoma.
Interferon has also been investigated in in  vitro and 
xenograft models [107] but its evaluation in the EURA-
MOS-1 trial showed no apparent advantage [108, 109].
Histological response to induction therapy has been 
accepted as a robust prognostic indicator [62, 91, 100, 
110]. Imaging techniques to identify response preop-
eratively, such as FDG-PET [111] and dynamic (diffusion 
weighted) MRI [112] are under investigation.
Changing postoperative chemotherapy on the basis of 
response has not been shown to improve outcome, and is 
not recommended at present [42].
The use of haematopoietic growth factors to increase 
dose intensity has not consistently resulted in improved 
survival of osteosarcoma patients [95] but may limit mor-
bidity associated with myelosuppression. Prophylactic 
antibiotics are now recommended for cancer patients at 
risk of neutropenic sepsis [113].
Central, parosteal and craniofacial osteosarcomas
Low-grade central and parosteal osteosarcoma are vari-
ants with lower malignant potential, for which treat-
ment is surgical. Histological examination of the resected 
tumour may show high grade areas in which case treat-
ment should be with chemotherapy as for conventional 
osteosarcoma.
The exact role of chemotherapy has not been defined 
for periosteal and jaw osteosarcoma but experience 
shows that standard chemotherapy can be given and 
should be considered for all patients at presentation as 
part of evaluation by an experienced MDT. Jaw and other 
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craniofacial osteosarcomas present specific problems 
for management, especially to achieve local control, and 
must always be referred to a bone sarcoma MDT before 
surgery. 18FDG PET is more reliable than standard imag-
ing in evaluating response to neoadjuvant chemotherapy 
in craniofacial bone sarcomas and may correlate better 
with outcome than histological response [114].
Metastatic disease
Patients presenting with metastatic osteosarcoma are a 
heterogeneous group and may be treated using the same 
regimens as for non-metastatic osteosarcomas, provided 
that surgical resection of all disease sites is deemed fea-
sible [115]. Approximately 30 % of patients with primary 
metastatic osteosarcoma and over 40  % of those who 
achieve complete surgical remission become long-term 
survivors [93].
Recurrent disease
The prognosis for recurrent disease is poor, with long-
term post-relapse survival of less than a third [93]. Early 
relapse and distant non-lung metastases are associated 
with a poorer prognosis [116].
Treatment for locally recurrent or metastatic osteo-
sarcoma is primarily surgical, if possible. Pulmonary 
metastatectomy can lead to long term survival if all 
metastases can be completely removed [117]. More 
than a third of patients with a second surgical remis-
sion survive for over 5  years, and patients with multi-
ple recurrences may be cured as long as recurrences are 
resectable: repeated thoracotomies are often warranted 
[118]. However, if pulmonary metastases are inoperable 
the disease is almost universally fatal.
The role of second-line chemotherapy for recurrent 
osteosarcoma is less well defined than that of surgery 
and there is no accepted standard regimen [93, 115]. The 
choice of agents may take into account the prior disease-
free interval; suggested regimens are shown in Table  3 
[98].
Second-line chemotherapy is associated with lim-
ited prolongation of survival in patients with inoperable 
metastases, but a positive benefit in operable disease was 
observed in one series [119–121]. Radiotherapy, includ-
ing samarium, may palliate inoperable sites [4, 122].
Agents targeting the epidermal growth factor receptor 
are investigational in patients with unresectable disease 
failing first-line therapy [123].
Treatment evaluation
Assessment of response is usually only possible after sev-
eral cycles of chemotherapy. Changes in the size and ossi-
fication of the tumour do not reliably reflect response to 
neoadjuvant chemotherapy. However, reduction in peritu-
moural oedema seen on MRI indicates a good treatment 
response [124]. A small study showed PET/CT is more 
accurate than MRI for following bone lesions [58, 125] but 
confirmation in larger prospective studies is needed.
Key recommendations
  • Treatment for osteosarcoma involves chemotherapy 
and surgery under the care of a specialist bone sar-
coma MDT.
  • Patients should be informed about relevant clinical 
trials and supported to enter them.
  • First line standard treatment is MAP chemotherapy 
for patients under 40 years.
  • Mifamurtide may be offered to patients without 
metastases after surgery.
  • Treatment of the primary tumour should be surgical 
removal of the tumour with negative surgical mar-
gins where feasible.
  • The adequacy of local clearance should be assessed 
by considering the response to chemotherapy and the 
surgical margin.
  • Radiotherapy can be offered for local control where 
surgical removal is not possible.
  • Where pulmonary metastases are present successful 
excision may prolong survival.
  • The primary treatment of recurrent disease is surgi-
cal although there is a role for chemotherapy.
Ewing sarcoma
Prognostic factors for Ewing sarcoma include axial loca-
tion, tumour volume, raised serum LDH, and older age 
(>15  years). A poor histological response to preop-
erative chemotherapy and incomplete or no surgery for 
local therapy are further adverse prognostic factors [89, 
126–128].
Table 3 Sarcoma advisory group guidelines for osteosarcoma
Taken from: London and South East Sarcoma Network (LSESN) Guidelines [98]
Category 1st line 2nd line 3rd line and other
Resectable <30 years Doxorubicin, cisplatin  
methotrexate ± mifamurtide [101]
Ifosfamide and etoposide [102] Gemcitabine and docetaxel 
[103] or oral etoposide
Other Doxorubicin, cisplatin ± methotrexate [101] Ifosfamide, etoposide ± methotrexate Gemcitabine and docetaxel 
[103] or oral etoposide
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Ewing Sarcoma is a radiosensitive tumour. Radiother-
apy may be used in combination with surgery, where 
there is a poor response to chemotherapy (radiological or 
histological), if there are concerns about surgical resec-
tion margins [129, 130] or if the anatomical site makes 
complete resection impossible. Radiotherapy may be 
given to the primary tumour site preoperatively, postop-
eratively or as definitive local therapy where surgery is 
not possible.
With surgery or radiotherapy alone, 5-year survival for 
Ewing sarcoma is <10 %. With treatment in current mul-
timodality trials including chemotherapy, 5-year survival 
is between 60 and 70  % in localized and 20 to 40  % in 
metastatic disease [4].
Localised disease
All current trials employ 10 to 12  months of treatment 
comprising three to six cycles of neoadjuvant chemo-
therapy, followed by local therapy and a further six to ten 
cycles of chemotherapy usually given at 2 or 3 week inter-
vals and based on current agreed national or interna-
tional protocols. Agents considered most active include 
doxorubicin, cyclophosphamide, ifosfamide, vincristine, 
dactinomycin and etoposide [23, 89, 127, 130–139]. The 
LSEN guidelines [98] are summarized in Table  4. Vir-
tually all active protocols are based on four to six drug 
combinations of these agents. Chemotherapy intensity 
is positively associated with outcome: superior outcome 
has been demonstrated with compressed 2 weekly chem-
otherapy [140]. High dose chemotherapy with blood stem 
cell transplantation is still investigational [141].
Local treatment may comprise surgery or radiother-
apy or both. Individual decisions about local therapy 
are frequently complex and should only be made by a 
bone sarcoma MDT in conjunction with the patient and 
their family if appropriate. It is also recommended that 
the MDT’s treatment plan is then discussed at the UK 
National Ewings MDT (ROH-tr.ewingsMDT@nhs.net) 
and entry into a clinical trial considered. At the time of 
writing (2015), the EE2012 trial is still open [151].
Complete surgery is regarded as the best treatment 
for local control but may not always be feasible. There is 
increasing recognition of the importance of treating all 
tissue initially involved by tumour, even if there has been 
a good response to chemotherapy. If this volume can-
not confidently be removed surgically then radiotherapy 
should be used.
Indications for planned preoperative radiotherapy 
include poor response to induction chemotherapy, 
expected marginal resection, or if radiotherapy is antic-
ipated to be required and the bone sarcoma MDT 
judges there is a technical advantage to preoperative 
radiotherapy.
Preoperative radiotherapy may also be useful in par-
ticular anatomical locations (e.g. pelvis, rib) when pre-
operative treatment allows the tumour volume to be 
defined more easily, or when treatment volumes will be 
smaller than in the post-operative setting. Radiotherapy 
alone should be considered if complete surgery is impos-
sible or would be very disabling, (e.g. for sacral tumours 
crossing the midline) [152, 153]. If standard conformal 
radiotherapy will not achieve an adequate dose to the 
tumour, techniques such as IMRT (intensity modulated 
radiotherapy) may deliver a higher dose [154–156]. 
Insertion of pelvic spacers can displace bowel away from 
pelvic tumours, facilitating delivery of a higher dose and 
preventing long term bowel toxicity [157]. Proton beam 
radiotherapy may be considered when there is a dosi-
metric advantage over photon radiotherapy in achiev-
ing the optimal radiotherapy dose due to proximity to 
critical structures such as spinal cord, and for younger 
patients having curative treatment in order to reduce the 
risk of radiation-induced second malignancy. Applica-
tions for treatment are made via the UK Proton Panel 
[83]).
Toxicities leading to death have been observed in 
some patients who received high dose large volume 
radiotherapy following busulpan-melphalan high dose 
chemotherapy (BuMel HDT). BuMel HDT may therefore 
compromise the delivery of effective radiation doses to 
central axial sites. In patients with an indication for radi-
otherapy, the patient should not be offered BuMel HDT if 
there are critical organs such as gut, spinal cord, brain or 
significant volumes of lung in the fields, unless the tech-
nique used can limit the dose to critical organs.
Specific indications for post-operative radiotherapy 
include (Taken from: Euro-Ewing-2012 radiotherapy 
guidelines [158]):
  • positive surgical margins with microscopic residual 
disease (R1 excision; <1  mm or tumour up to edge 
of resection specimen) if further surgery to achieve 
negative margins is not possible.
  • positive surgical margins with macroscopic residual 
disease (R2 excision), if further surgery to achieve 
negative margins is not possible (this should be an 
unusual situation).
  • if all tissues involved by the original pre-chemother-
apy tumour volume have not been excised, even if 
the surgical margins are negative.
  • if there is a poor histological response (≤90 % necro-
sis) to pre-operative chemotherapy, even if the surgi-
cal margins are negative.
  • a displaced pathological fracture of bone at primary 
site (unless it is possible to excise all contaminated 
tissue).
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  • certain tumour sites where local control is judged to 
be more difficult to achieve e.g.:
•  Spine and paraspinal sites—in these sites excision 
is rarely complete, and is often intra-lesional.
•   Pelvis and sacrum—in these sites it is frequently 
difficult or impossible to be sure that the entire pre-
chemotherapy tumour volume has been excised.
•   Rib tumours when presenting with a pleural effusion.
Reasons for deciding against radiotherapy may include:
  • Concerns about impaired healing of the wound or 
biological reconstruction following surgery and radi-
otherapy.
  • Concerns about morbidity of radiotherapy in young 
patients.
  • Concerns about the increased risk of infection of a 
metallic prosthesis following radiotherapy.
  • Concerns about the risk of a radiation-induced 
malignancy.
Definitive radiotherapy is advised only for inoperable 
lesions. Inoperability is determined during bone sarcoma 
MDT discussion. Inoperable tumours are those which 
cannot be resected completely, or are in anatomical sites 
where complete surgery would result in unacceptable 
morbidity or have a high risk of significant complications. 
Suggested radiotherapy doses are given in Table 5.
Metastatic and recurrent disease
Around 26 % of patients with Ewing sarcoma have meta-
static disease at presentation (10  % lung, 10  % bones/
bone marrow, 6  % combinations or others) [159]. Bone 
metastases confer a poorer outcome than lung/pleural 
metastases (<21  % compared with 55  % 5-year relapse 
free survival) [143].
Patients with metastases at diagnosis are treated simi-
larly to those with localised disease but have a poorer 
prognosis. Several non-randomised trials have evaluated 
more intensive, time compressed or high-dose chemo-
therapy approaches, followed by autologous stem cell 
rescue, demonstrating a possible advantage for patients 
under 14 years of age [143, 147]. Whole lung radiother-
apy is indicated in patients with pulmonary disease, and 
may prolong survival. However, firm data are lacking and 
a systematic review failed to confirm a survival advantage 
[160]. Radiation doses are given in Table 6.
A recent review of stereotactic body radiotherapy 
(SBRT) for metastatic and recurrent Ewing sarcoma and 
osteosarcoma reported on 14 patients with 27 osseous 
or pulmonary lesions. Estimated local control at 2 years 
in the lesions treated with curative intent was 85  %. 
However, there was significant toxicity especially if con-
current chemotherapy and re-irradiation were given 
[161].
The role of surgical resection of residual metastases 
is less well defined. Patients with bone or bone marrow 
metastases and patients with recurrent disease still fare 
poorly, with 5-year survival rates of between 10 and 45 % 
[24, 162, 163].
Guidance on the management of small suspicious lung 
nodules is available in trial protocols [108, 131].
Patients relapsing more than 2 years after diagnosis and 
without bone marrow or multiple bone involvement have 
a better outcome than others [126, 162, 164, 165].
Table 5 Radiotherapy dose and fractionation for ewing sarcoma
Fractionation: conventionally fractionated radiotherapy (once daily fractions, five 1.8 Gy fractions per week) is the preferred fractionation schedule. In very young 
children, fractionation using 1.6 Gy fractions may be considered
Taken from: Euro–Ewing-2012 radiotherapy guidelines [158]
Setting Dosage
Pre-operative radiotherapy The total dose for preoperative irradiation is 50.4 Gy in 28 fractions in a single phase to the PTV. If there are concerns 
about organ tolerance or wound healing, then this dose can be reduced to 45 Gy in 25 Gy fractions
Post-operative radiotherapy The total dose for postoperative radiotherapy is 54 Gy in 30 fractions, delivered as 45 Gy in 25 fractions to PTV1, and 9 Gy 
in 5 fractions to PTV2
Definitive radiotherapy The total dose for definitive radiotherapy is 54 Gy in 1.8 Gy fractions, delivered as a single phase. A boost of 5.4 Gy in 3 
fractions may be considered if desired, keeping within standard normal tissue dose constraints
Table 6 Radiotherapy doses for whole lung radiotherapy
Taken from: Euro–Ewing-2012 Radiotherapy Guidelines [158]
Whole lung radiotherapy The dose for whole lung radiotherapy is 15 Gy in 10 fractions for patients <14 years, or 18 Gy in 12 fractions for patients 
≥14 years. Dose may be specified to 100 % for an optimised plan, or to the mid plane dose (MPD) for simulated opposed 
fields. However, it should be noted that this will result in a dose of approximately 10 % higher in the lungs than that pre-
scribed, and so optimisation of dosimetry is recommended if fields are simulated
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Doxorubicin therapy is usually not feasible after relapse 
because of previously administered cumulative doses. 
Chemotherapy regimens are not standardised and cur-
rently often comprise alkylating agents (cyclophos-
phamide, high-dose ifosfamide) in combination with 
topoisomerase inhibitors (etoposide, topotecan) or iri-
notecan with temozolomide [23, 133, 137, 138]. Given 
the poor outcomes after relapse, patients should be 
recruited to prospective clinical trials to investigate the 
role of second-line/experimental therapies wherever pos-
sible. At time of writing, an international trial, rEECur, is 
open to recruitment [151]. Radiotherapy may be helpful 
to palliate local symptoms.
Treatment evaluation
Change in the size of the soft tissue mass is easily eval-
uated on MRI, and is a reliable indicator of tumour 
response [166]. Dynamic MRI is not as reliable as in 
osteosarcoma, as remaining small tumour foci may not 
be detected. Sequential FDG PET evaluation and whole 
body MRI scanning is under evaluation [53, 112].
Disease progression during chemotherapy may man-
date changes in treatment or earlier primary local control 
measures. A radiological increase in tumour size may be 
due to necrosis rather than tumour progression.
Key recommendations
  • For Ewing sarcoma, systemic treatment with chemo-
therapy is standard. All new cases of Ewing’s sarcoma 
of bone should be discussed at the National Ewing 
Multidisciplinary Team meeting.
  • When treating the primary tumour with curative 
intent, all of the pre-chemotherapy volume should be 
treated with surgery, radiotherapy or both.
  • If radiotherapy is indicated (e.g. the anatomical loca-
tion of the tumour makes complete resection impos-
sible or there has been an incomplete response to 
chemotherapy as identified radiologically), then pre-
operative radiotherapy may be advantageous.
  • Patients with relapsed/progressive disease should be 
considered for clinical trials.
Chondrosarcoma
Assessing the grade of chondrosarcomas is difficult and 
variation in opinion is common, even between experts 
[28]. The diagnosis of chondrosarcoma requires discus-
sion in a bone sarcoma MDT. Surgery is the treatment of 
choice.
Low grade cartilage tumours may recur locally but 
are unlikely to metastasise. Biopsy-confirmed low grade 
central chondrosarcomas in extremity long bones can be 
managed by complete curettage with or without adjuvant 
measures (e.g. phenol, cement, cryotherapy) with a high 
chance of success. Low grade peripheral chondrosar-
comas (arising from osteochondromas) should be com-
pletely surgically removed, aiming to excise the tumour 
with a covering of normal tissue.
Higher grade chondrosarcomas (including clear cell 
chondrosarcoma) and all chondrosarcomas of the pelvis 
or axial skeleton should be surgically excised with wide 
margins [29, 30].
Mesenchymal chondrosarcoma may be responsive 
to chemotherapy and some patients may be consid-
ered for adjuvant or neoadjuvant therapy [114]. There 
is uncertainty about the chemotherapy sensitivity of 
dedifferentiated chondrosarcoma but it can be treated 
like osteosarcoma, although survival is poorer [31]. 
Survival after a diagnosis of dedifferentiated chondro-
sarcoma remains dismal. Complete excision is recom-
mended if feasible, but there is a very high risk of local 
recurrence following pathological fracture. If wide 
margins cannot be reliably achieved with limb salvage, 
then amputation may maximize the chances of local 
control but there remains a high risk that metastases 
will develop.
Key recommendations
  • Diagnosis of a chondrosarcoma requires discussion 
in a bone sarcoma MDT.
  • Management of chondrosarcoma is surgical excision 
with wide margins for all but low grade central limb 
chondrosarcoma where curettage may be adequate.
  • There are no data to support the routine use of 
chemotherapy.
Undifferentiated pleomorphic sarcomas.
Treatment strategies mimic those of osteosarcoma, with 
age-adjusted chemotherapy and complete en-bloc resec-
tion including any soft tissue component if possible.
Chordoma
Assessment in a specialist centre with expertise in 
managing chordomas is essential. To date, conventional 
therapy for chordoma has been complete surgical 
resection [167]. High dose radiotherapy using proton 
beams or carbon ions may be used post-operatively, 
and are promising alternatives to surgery for some 
patients, particularly those with high sacral tumours 
[74, 81, 82].
Surgical excision of tumours of the skull base or cervi-
cal spine should aim to remove as much tumour as possi-
ble, whilst preserving neurological function and therefore 
quality of life. R0 resection is rarely possible. Eight stud-
ies (summarized by Stacchiotti et  al. [35]) have shown 
that surgery (R1 and R2 resections) followed by radio-
therapy in selected patients produced 5-year estimated 
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overall survival of 55–86 % in patients with chordoma of 
the skull base and/or cervical spine.
Metastases are rare but local recurrence is common 
and difficult to cure [168]. Treatment for local recurrence 
may include surgery and/or radiation therapy and/or 
systemic treatment (Table 7) [4, 35]. Molecular targeted 
agents may be effective [169, 170].
Other bone sarcomas
Prognosis and prognostic factors after a diagnosis of 
spindle cell sarcoma are similar to those of patients with 
osteosarcoma [41, 171, 172]. Treatment should be similar.
Adamantinoma is a malignant tumour occurring in the 
tibia. Most are low grade but higher grade areas in the 
primary tumour may require systemic therapy. Complete 
excision is the treatment of choice.
Giant cell tumours of bone
Giant cell tumours of bone require highly specialised 
treatment and all patients should be referred to a spe-
cialist bone sarcoma MDT for diagnosis and to coordi-
nate treatment. Curettage alone is associated with a high 
risk of local recurrence (up to 50  %). Although there is 
no randomized controlled trial evidence, numerous case 
series suggest improved local control if adjuvants such as 
high speed burring and cement are used.
Denosumab is a novel RankL inhibitor which has been 
shown in clinical trials to suppress the formation and 
activity of osteoclasts. It is licensed for use by the Euro-
pean medicines agency from 2014. Denosumab is indi-
cated in inoperable cases or those where the morbidity 
of surgery would be excessive. Denosumab is given as a 
monthly subcutaneous injection after three loading doses 
at weekly intervals. All patients require daily calcium and 
vitamin D supplements and females must avoid preg-
nancy. Significant side effects include hypocalcaemia, 
osteonecrosis of the jaw and atypical fractures [173, 174].
Emerging evidence suggests that whilst initial con-
trol is excellent (96  %), later recurrences can arise and 
most tumours recur if the drug is stopped (after around 
9 months). Hence in inoperable cases life-long treatment 
may be required. The consequences of this, particularly 
in younger patients, are not known.
Using denosumab to reduce the size of a giant cell 
tumour prior to surgery may be advantageous but sur-
gery should incorporate the extent of the original tumour 
to avoid recurrence. While clear guidance on the optimal 
duration of pre-operative treatment has yet to emerge, 
prolonged exposure to denosumab may make subsequent 
curettage more difficult. Treatment for up to 6  months 
before surgery is a reasonable pragmatic approach.
Follow‑up
Follow-up after treatment aims to detect local recur-
rence, to detect metastatic disease for which treatment 
might be beneficial, to manage the long term toxicity 
of chemotherapy and radiotherapy and to look for long 
term complications of surgical treatment [4]. Local 
recurrences are often first detected by patients and there-
fore they should be given information about what to do if 
local recurrence is suspected.
The clinical follow-up of patients treated for high-grade 
tumours should include physical examination of the pri-
mary tumour site, and assessment of the functional out-
come and possible complications of any reconstruction. 
Local and chest imaging should be included. Evidence for 
the optimum frequency of follow-up and the best imag-
ing investigations is lacking although a recently reported 
randomised controlled trial showed no benefit of greater 
frequency of follow-up with regular cross sectional imag-
ing over standard follow-up [178]. However, current pro-
tocols recommend follow-up at intervals of 2–4 months 
for the first 3  years after completion of therapy, every 
6  months for year 4 and 5 and annually thereafter [24, 
93].
For low grade bone sarcomas, the frequency of fol-
low-up visits can be reduced to 4–6 monthly for 2 years 
and then annually. Late metastases as well as local 
Table 7 Sarcoma advisory group guidelines—bone sarcomas
Taken from London and South East Sarcoma Network (LSESN) guidelines [98]
Sarcoma type Category 1st line 2nd line 3rd line and other
Other high grade bone sar-
comas including malignant 
fibrous histiocytoma, leio-
myosarcoma, angiosarcoma, 
spindle cell sarcoma, dedif-
ferentiated chondrosarcoma
Doxorubicin,  
cisplatin ± methotrexate 
[101]
Ifosfamide,  
etoposide  ± methotrexate 
[102]
Gemcitabine and  
docetaxel [103]
Giant cell tumour Locally advanced  
unresectable/metastatic
Denosumab [175]
Chordoma Locally advanced, unresectable or  
metastatic: non-dedifferentiated  
dedifferentiated
Imatinib [171] doxorubicin  
or doxorubicin and  
cisplatin [176]
Addition of sirolimus [170]
or Sunitinib [177]
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recurrences and failure of reconstructions may occur 
more than 10  years after diagnosis in all tumours and 
there is no universally accepted stopping point for fol-
low-up [4].
It is important to evaluate the long-term toxicity effect 
of chemotherapy and radiotherapy as well as immediate 
chemotherapy-related complications [64]. Monitoring 
for late effects should be undertaken, depending on the 
treatment given and in conjunction with late effect ser-
vices when available [127, 179, 180].
Secondary cancers may arise in survivors of bone sar-
comas, either related to or independent of irradiation. 
Secondary leukaemia, particularly acute myeloid leukae-
mia may rarely be observed following chemotherapy as 
early as 2–5 years after treatment [181, 182].
Key recommendations
  • Standard follow-up for all sarcoma cases is currently 
chest X-ray and clinical review. The role of regular 
cross sectional imaging remains uncertain.
  • At the end of treatment patients should receive infor-
mation about the risk of local and systemic recur-
rence.
  • Patients should have access to services for the late 
effects of treatment including chemotherapy, radio-
therapy, surgery and psychsocial support.
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